脊髓胶质母细胞瘤治疗方式的差异:来自国家癌症登记数据库的结果
基于美国国家癌症数据库2004至2014年数据,比较190例脊髓胶质母细胞瘤与103,496例颅脑胶质母细胞瘤的生存及治疗差异。脊髓胶质母细胞瘤中位生存高于颅脑胶质母细胞瘤(p=0.07),18至65岁年龄组生存显著优于<18岁和>65岁组(p=0.003)。95例有治疗数据的脊髓胶质母细胞瘤患者中,四种治疗方式总生存无统计学差异(p=0.28)。
要点
- 脊髓胶质母细胞瘤中位生存高于颅脑胶质母细胞瘤(p=0.07)。
- 18至65岁年龄组生存显著优于<18岁和>65岁组(p=0.003)。
- 四种治疗方式总生存无统计学差异(p=0.28)。
核心结论
- 脊髓胶质母细胞瘤中位生存高于颅脑胶质母细胞瘤(p=0.07)。
- 18至65岁年龄组生存显著优于<18岁和>65岁组(p=0.003)。
- 95例有治疗数据的脊髓胶质母细胞瘤患者中,四种治疗方式总生存无统计学差异(p=0.28)。
研究设计与样本
- 回顾性查询美国国家癌症数据库2004至2014年诊断为4级胶质母细胞瘤的患者。
- 共纳入103,496例颅脑胶质母细胞瘤和190例脊髓胶质母细胞瘤患者进行分析。
主要发现
- 脊髓胶质母细胞瘤中位生存高于颅脑胶质母细胞瘤(p=0.07)。
- 脊髓胶质母细胞瘤患者中18至65岁年龄组生存显著优于<18岁和>65岁年龄组(p=0.003)。
- 95例有治疗数据的脊髓胶质母细胞瘤患者中,放疗伴或不伴化疗、单纯手术、手术加辅助治疗及姑息治疗四种方式的总生存无统计学差异(p=0.28)。
- 多变量分析中,<18岁年龄组与生存改善相关(HR 0.50,95% CI 0.23-1.00,p=0.046),肿瘤延伸与生存不良相关(HR 2.71,95% CI 1.04-6.22,p=0.041)。
- 手术加辅助治疗与其他治疗方式相比未能显示生存增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Primary glioblastoma of the spinal cord (spinal GBM) is a rare central nervous system tumor, relative to its cranial counterpart (cranial GBM). Our current knowledge of spinal GBM epidemiology, tumor characteristics and treatment are insufficient and mostly based on single-institution case series. METHODS: All patients diagnosed with grade-4 GBM from 2004 to 2014 were queried from the National Cancer Database. Chi square analysis was used to compare presenting characteristics while Kaplan-Meier and Cox regression analyses were employed for survival analyses. RESULTS: Total 103,496 patients with cranial GBM and 190 patients with spinal GBM were analyzed. Median survival for spinal GBM was found to be higher compared to cranial GBM (p = 0.07). Spinal GBM patients had significant better survival in 18 to 65 years age group than < 18 years and > 65 years age group (p = 0.003). Overall survival time for 95 spinal GBM patients with available treatment data was not statistically different among the four treatment modalities (radiation with or without chemotherapy, surgery alone, surgery with adjuvant therapy, and palliative therapy; p = 0.28).On multivariable analysis, < 18 years age group was associated with improved survival (HR 0.50, 95% CI 0.23-1.00, p = 0.046), while tumor extension was associated with poor survival (HR 2.71, 95% CI 1.04-6.22, p = 0.041). Interestingly surgery with adjuvant therapy was unable to show increase survival compared to other treatment modalities. CONCLUSIONS: Our study adds to the growing literature on spinal GBM with a focus on comparative trends with cranial GBM and outcomes with different treatment modalities.
引用
- Moinuddin FM, Alvi MA, Kerezoudis P, et al. Variation in management of spinal gliobastoma multiforme: results from a national cancer registry. J Neurooncol. 2018. PMID: 30460627. doi:10.1007/s11060-018-03054-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。